Navigation Links
LightLab Highlights OCT Market Leadership at the Society for Cardiovascular Angiography and Interventions
Date:4/30/2010

WESTFORD, Mass., April 30 /PRNewswire/ -- LightLab Imaging, Inc., the pioneer in development and world leader in sales of Optical Coherence Tomography (OCT) systems for vascular and other imaging applications, will exhibit at the Society for Cardiovascular Angiography and Interventions (SCAI) meeting in San Diego, CA May 5 to 8, in booth 28.

Presenting at SCAI will be Marco A Costa, MD, PhD, Professor of Medicine Director, Interventional Cardiovascular Center and Director, Research and Innovation Center at the Harrington-McLaughlin Heart and Vascular Institute University Hospitals, Case Western Reserve University. He will deliver the talk, "Do I really need to see that much stent detail with OCT?" on Wednesday, May 5, from 11:00 AM to 11:15 AM.

"Cardiologists have long been searching for imaging tools to enhance our understanding of vascular disease and guide optimal PCI and other coronary therapeutic strategies," said Dr. Costa. "The LightLab's C7-XR™ imaging system is the first non-occlusive optical intravascular imaging system already available in Europe and Asia. Many have focused on the eye catching micron-level vascular images, but "ease-of-use" and speed at > 100 frames/sec are the key features of this imaging tool that will revolutionize the way real-world interventionalists approach coronary artery disease."

Dr. Costa directs the cardiovascular imaging core lab responsible for analyzing results from many trials using OCT. LightLab has submitted a 510(k) Premarket Notice which is under review by the Food and Drug Administration. LightLab OCT is not currently cleared for sale in the US.

Working with leading physicians worldwide, LightLab has led the clinical development of intravascular OCT applications and currently offers the only commercially available OCT systems. The company's FD-OCT™ or Frequency Domain OCT system has been available outside of the U.S. for the past year. LightLab's C7-XR systems are installed in many European countries, and thousands of FD-OCT imaging procedures have been performed with this system since its introduction.

"SCAI is an important show for LightLab and a great opportunity for us to demonstrate the clinical advantages of our products," said David Kolstad, CEO of LightLab Imaging. "The C7-XR system has provided clinicians in Europe a significant advancement in imaging speed and clinical data available to them during therapeutic procedures."

About LightLab Imaging, Inc.

LightLab Imaging, Inc., based in Westford MA, is the world's leading manufacturer and marketer of Optical Coherence Tomography (OCT) for vascular and other imaging applications. LightLab's OCT systems and imaging catheters are cleared for sale in 40 countries in Europe, Asia, the Middle East and South America. The company was founded in 1998 by the inventors of OCT, and has exclusive license to a broad range of OCT technologies and applications from MIT and other entities. The LightLab mission is to develop and distribute photonic imaging technologies that improve patients' wellbeing, enhance diagnostic medicine, improve outcomes, and reduce healthcare expenditures. With the ability to resolve real-time images to 15 micrometers, the LightLab Imaging OCT Imaging Systems offer physicians more precise information than ever before. For more information, visit www.lightlabimaging.com.

About LightLab OCT

LightLab Optical Coherence Tomography (OCT) is the Extreme Resolution™ imaging technology for cardiovascular disease diagnosis. LightLab OCT utilizes near-infrared light to create images with 10 times the resolution of Intravascular ultrasound (IVUS). The proprietary LightLab OCT interferometer analyzes reflected light waves to create our extreme resolution Golden Image™ for enhanced diagnosis and treatment decisions.

The bandwidths of infrared light utilized for OCT are far higher than ultrasound, resulting in greatly increased image resolution. In fact, LightLab OCT provides intravascular images with 15 micrometer axial resolution, about twice the size of a red blood cell. Despite providing this extreme resolution LightLab OCT is a radiation-free* imaging medium.

*OCT is not a source of ionizing radiation, such as X-rays.


'/>"/>
SOURCE LightLab Imaging, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Date Set for LightLab Damages Trial Against Volcano and Axsun
2. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
3. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
4. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
5. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
6. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
7. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
8. Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease
9. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
10. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
11. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... -- Commended for their devotion to personalized service, SMP Pharmacy Solutions ... in the South Florida Business Journal,s 50 Fastest-Growing Companies, and ... the national specialty pharmacy has found its niche.  To that ... be honored by SFBJ as the 2017 Power Leader in ... receive his award in October, Bardisa said of the three ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
Breaking Medicine Technology:
(Date:10/13/2017)... OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... or dementia. However, many long-term care insurance companies have a waiver for care if ... the 90-day elimination period, when the family pays for care, is often waived, so ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Yisrayl Hawkins, Pastor ... that explains one of the most popular and least understood books in the Holy ... and puzzling descriptions that have baffled scholars for centuries. Many have tossed it off ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and ... of published author, William Nowers. Captain Nowers and his wife, Millie, have six ... years in the Navy. Following his career as a naval aviator and carrier ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
Breaking Medicine News(10 mins):